Which has preferable valuation & earnings, IMRX or FLNA?

Immuneering is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.17 N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is IMRX or FLNA more profitable?

Immuneering's return on equity of -31.93% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% Cassava Sciences N/A -53.90% -34.20%

Does the media refer more to IMRX or FLNA?

In the previous week, Immuneering had 4 more articles in the media than Cassava Sciences. MarketBeat recorded 6 mentions for Immuneering and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat Immuneering's score of 0.86 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FLNA or ZNTL more profitable?

Zentalis Pharmaceuticals' return on equity of -53.61% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% Zentalis Pharmaceuticals N/A -53.61% -40.67%

Which has stronger valuation & earnings, NVCT or FLNA?

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is NVCT or FLNA more profitable?

Cassava Sciences' return on equity of -53.90% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -161.00% -98.88% Cassava Sciences N/A -53.90% -34.20%

Does the media prefer NVCT or FLNA?

In the previous week, Nuvectis Pharma and Nuvectis Pharma both had 2 articles in the media. Nuvectis Pharma's average media sentiment score of 1.31 beat Cassava Sciences' score of 0.93 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MGNX or FLNA?

In the previous week, MacroGenics had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 3 mentions for MacroGenics and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat MacroGenics' score of 0.63 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cassava Sciences (FLNA) Competitors

$1.25 0.00 (0.00%)

As of 06/12/2026 04:00 PM Eastern

Compare

FLNA vs. IMRX, ZNTL, EDIT, NVCT, and MGNX

Should you buy Cassava Sciences stock or one of its competitors? MarketBeat compares Cassava Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cassava Sciences include Immuneering (IMRX), Zentalis Pharmaceuticals (ZNTL), Editas Medicine (EDIT), Nuvectis Pharma (NVCT), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry.

How does Cassava Sciences compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Immuneering presently has a consensus price target of $16.50, indicating a potential upside of 293.79%. Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 300.00%. Given Cassava Sciences' higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Immuneering is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Immuneering's return on equity of -31.93% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Cassava Sciences	N/A	-53.90%	-34.20%

67.7% of Immuneering shares are held by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are held by institutional investors. 22.9% of Immuneering shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Immuneering had 4 more articles in the media than Cassava Sciences. MarketBeat recorded 6 mentions for Immuneering and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat Immuneering's score of 0.86 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market.

Summary

Immuneering beats Cassava Sciences on 11 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Zentalis Pharmaceuticals?

Cassava Sciences (NASDAQ:FLNA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Cassava Sciences has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Zentalis Pharmaceuticals	$67.43M	3.96	-$137.06M	-$1.73	N/A

Zentalis Pharmaceuticals' return on equity of -53.61% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

38.0% of Cassava Sciences shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cassava Sciences presently has a consensus price target of $5.00, suggesting a potential upside of 300.00%. Zentalis Pharmaceuticals has a consensus price target of $5.83, suggesting a potential upside of 55.56%. Given Cassava Sciences' higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Cassava Sciences had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 2 mentions for Cassava Sciences and 1 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.89 beat Cassava Sciences' score of 0.93 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cassava Sciences	Positive
Zentalis Pharmaceuticals	Very Positive

Cassava Sciences has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

Summary

Cassava Sciences beats Zentalis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Editas Medicine?

Cassava Sciences (NASDAQ:FLNA) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Cassava Sciences currently has a consensus price target of $5.00, indicating a potential upside of 300.00%. Editas Medicine has a consensus price target of $5.40, indicating a potential upside of 116.00%. Given Cassava Sciences' higher possible upside, equities research analysts clearly believe Cassava Sciences is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Cassava Sciences and Cassava Sciences both had 2 articles in the media. Cassava Sciences' average media sentiment score of 0.93 beat Editas Medicine's score of 0.43 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cassava Sciences	Positive
Editas Medicine	Neutral

38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cassava Sciences has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Editas Medicine	$40.52M	6.04	-$160.06M	-$1.23	N/A

Cassava Sciences has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market.

Cassava Sciences has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Cassava Sciences' return on equity of -53.90% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Editas Medicine	-281.59%	-677.39%	-58.25%

Summary

Cassava Sciences beats Editas Medicine on 8 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Nuvectis Pharma presently has a consensus target price of $13.00, suggesting a potential upside of 21.38%. Cassava Sciences has a consensus target price of $5.00, suggesting a potential upside of 300.00%. Given Cassava Sciences' higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cassava Sciences' return on equity of -53.90% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
Cassava Sciences	N/A	-53.90%	-34.20%

Nuvectis Pharma has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.71, indicating that its stock price is 171% less volatile than the broader market.

In the previous week, Nuvectis Pharma and Nuvectis Pharma both had 2 articles in the media. Nuvectis Pharma's average media sentiment score of 1.31 beat Cassava Sciences' score of 0.93 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are owned by institutional investors. 28.5% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Summary

Nuvectis Pharma beats Cassava Sciences on 6 of the 10 factors compared between the two stocks.

How does Cassava Sciences compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

In the previous week, MacroGenics had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 3 mentions for MacroGenics and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat MacroGenics' score of 0.63 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MacroGenics has higher revenue and earnings than Cassava Sciences. MacroGenics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.68	-$74.62M	-$1.10	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

MacroGenics currently has a consensus price target of $5.50, indicating a potential upside of 38.89%. Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 300.00%. Given Cassava Sciences' higher probable upside, analysts clearly believe Cassava Sciences is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MacroGenics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.71, suggesting that its stock price is 171% less volatile than the broader market.

Cassava Sciences has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Cassava Sciences' return on equity of -53.90% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
Cassava Sciences	N/A	-53.90%	-34.20%

Summary

MacroGenics beats Cassava Sciences on 10 of the 15 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLNA vs. The Competition

Export

Metric	Cassava Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$60.39M	$2.99B	$6.52B	$12.05B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-0.78	18.84	24.00	24.42
Price / Sales	N/A	326.45	515.84	118.72
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	0.81	3.98	10.60	6.82
Net Income	-$90.97M	$75.79M	$3.57B	$337.56M
7 Day Performance	-12.59%	1.57%	0.59%	1.16%
1 Month Performance	5.93%	-0.73%	1.54%	3.16%
1 Year Performance	-39.02%	23.44%	25.41%	30.60%

Cassava Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLNA Cassava Sciences	1.7346 of 5 stars	$1.25 flat	$5.00 +300.0%	-39.0%	$60.39M	N/A	N/A	20
IMRX Immuneering	2.7144 of 5 stars	$4.12 -3.6%	$16.50 +301.0%	+120.5%	$266.89M	N/A	N/A	60	Analyst Downgrade
ZNTL Zentalis Pharmaceuticals	2.5361 of 5 stars	$3.70 +1.1%	$5.83 +57.7%	+179.9%	$263.74M	N/A	N/A	160
EDIT Editas Medicine	2.8527 of 5 stars	$2.65 -2.4%	$5.40 +104.2%	+26.9%	$259.94M	$38.69M	N/A	230	Short Interest Increase
NVCT Nuvectis Pharma	1.9249 of 5 stars	$9.55 +0.1%	$10.00 +4.7%	+27.3%	$253.36M	N/A	N/A	8	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLNA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cassava Sciences (FLNA) Competitors

FLNA vs. IMRX, ZNTL, EDIT, NVCT, and MGNX

How does Cassava Sciences compare to Immuneering?

Summary

How does Cassava Sciences compare to Zentalis Pharmaceuticals?

Summary

How does Cassava Sciences compare to Editas Medicine?

Summary

How does Cassava Sciences compare to Nuvectis Pharma?

Summary

How does Cassava Sciences compare to MacroGenics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cassava Sciences (FLNA) Competitors

FLNA vs. IMRX, ZNTL, EDIT, NVCT, and MGNX

How does Cassava Sciences compare to Immuneering?

Do analysts recommend IMRX or FLNA?

Which has preferable valuation & earnings, IMRX or FLNA?

Is IMRX or FLNA more profitable?

Do institutionals & insiders believe in IMRX or FLNA?

Does the media refer more to IMRX or FLNA?

Which has more volatility and risk, IMRX or FLNA?

Summary

How does Cassava Sciences compare to Zentalis Pharmaceuticals?

Which has preferable earnings & valuation, FLNA or ZNTL?

Is FLNA or ZNTL more profitable?

Do insiders & institutionals have more ownership in FLNA or ZNTL?

Do analysts recommend FLNA or ZNTL?

Does the media refer more to FLNA or ZNTL?

Which has more volatility and risk, FLNA or ZNTL?

Summary

How does Cassava Sciences compare to Editas Medicine?

Do analysts rate FLNA or EDIT?

Does the media prefer FLNA or EDIT?

Do insiders and institutionals believe in FLNA or EDIT?

Which has higher earnings and valuation, FLNA or EDIT?

Which has more volatility and risk, FLNA or EDIT?

Is FLNA or EDIT more profitable?

Summary

How does Cassava Sciences compare to Nuvectis Pharma?

Do analysts rate NVCT or FLNA?

Is NVCT or FLNA more profitable?

Which has more volatility & risk, NVCT or FLNA?

Does the media prefer NVCT or FLNA?

Do insiders & institutionals hold more shares of NVCT or FLNA?

Which has stronger valuation & earnings, NVCT or FLNA?

Summary

How does Cassava Sciences compare to MacroGenics?

Does the media prefer MGNX or FLNA?

Which has better earnings & valuation, MGNX or FLNA?

Do analysts prefer MGNX or FLNA?

Do institutionals and insiders believe in MGNX or FLNA?

Which has more volatility and risk, MGNX or FLNA?

Is MGNX or FLNA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools